Valuation: Solid Biosciences Inc.

Market Cap 972M 843M 790M 720M 1.36B 92.77B 1.38B 9.3B 3.63B 46.44B 3.65B 3.57B 155B P/E 2026 *
-5.21x
P/E 2027 * -5.27x
Enterprise Value 678M 588M 551M 502M 945M 64.69B 960M 6.49B 2.53B 32.38B 2.54B 2.49B 108B EV / Sales 2026 *
-
EV / Sales 2027 * 169x
Free-Float
88.22%
Yield 2026 *
-
Yield 2027 * -
1 day+0.17%
1 week+4.01%
Current month+12.66%
1 month-12.86%
3 months+17.62%
6 months+49.34%
Current year+60.99%
1 week 8.29
Extreme 8.29
9.26
1 month 7.65
Extreme 7.65
9.94
Current year 4.92
Extreme 4.92
11.45
1 year 3.79
Extreme 3.79
11.45
3 years 1.81
Extreme 1.81
15.05
5 years 1.81
Extreme 1.81
51.3
10 years 1.81
Extreme 1.81
822.6
Manager TitleAgeSince
Chief Executive Officer 55 2022-12-01
Corporate Officer/Principal - 2014-08-31
Director of Finance/CFO 48 2023-01-08
Director TitleAgeSince
Director/Board Member 52 2013-02-28
Director/Board Member 60 2015-10-31
Director/Board Member 46 2015-10-31
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Fiscal year

Chairman

6,880 0.0070%
6/10/26 Free

Founder

77,500 0.0787%
2/13/26 Fiscal year

Chief Operating Officer

36,843 0.0473%
Change 5-day change 1-year change 3-year change Capi.($)
+0.17%+4.01%+50.33%+138.95% 972M
+2.07%+10.05%+77.41%+106.53% 70.1B
-0.87%+0.77%+36.57%+65.91% 54.93B
-4.50%+27.58%+3.55%+463.22% 28.89B
+0.04%+12.56%+54.67%+5.47% 23.9B
-0.67%-0.07%-17.01%-13.84% 23.3B
+0.35%+8.24%+252.94%+466.50% 18.41B
-0.59%+7.03%+46.32%-20.56% 18.77B
-0.57%+6.85%+30.20%+580.70% 16.1B
+0.46%-10.74%+33.36%+135.18% 12.48B
Average -0.41%+7.76%+56.83%+192.80% 26.78B
Weighted average by Cap. -0.21%+8.02%+55.72%+162.96%

Financials

2026 *2027 *
Net sales - 4.15M 3.6M 3.37M 3.07M 5.78M 396M 5.88M 39.69M 15.5M 198M 15.58M 15.24M 661M
Net income -224M -195M -182M -166M -313M -21.42B -318M -2.15B -838M -10.72B -843M -824M -35.77B -238M -206M -193M -176M -331M -22.67B -337M -2.27B -887M -11.35B -892M -873M -37.86B
Net Debt -294M -255M -239M -218M -410M -28.07B -417M -2.81B -1.1B -14.05B -1.1B -1.08B -46.88B -270M -234M -219M -200M -376M -25.72B -382M -2.58B -1.01B -12.88B -1.01B -990M -42.95B
Logo Solid Biosciences Inc.
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Employees
121
Date Price Change Volume
26-08-13 US$9.080 +0.17% 828,054
26-08-12 US$9.065 +2.43% 744,824
26-08-11 US$8.850 +3.39% 900,475
26-08-10 US$8.560 +2.03% 1,007,383
26-08-07 US$8.390 -3.67% 1,054,938
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
9.080USD
Average target price
17.64USD
Spread / Average Target
+94.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SLDB Stock